IL17A and Alzheimer disease: A former study detected the attenuation of AD symptoms, abated degranulated mast cells, reduced IL-5, CCL5 and IL-17, as well as macrophage inflammatory protein-2 (MIP2) in an AD mouse model, followed by the administration of human adipose tissue MSCs.